Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

New Study Shows Brachytherapy And Cesium-131 Isotope Treatment Beneficial For Prostate Cancer Patients

IsoRay Medical
Posted on: 01 Aug 17
New Study Shows Brachytherapy And Cesium-131 Isotope Treatment Beneficial For Prostate Cancer Patients Medical community still battles acceptance of patient-friendly solution with proven reduced side effects and long-term symptoms

PR Newswire

RICHLAND, Wash., Aug. 1, 2017

RICHLAND, Wash., Aug. 1, 2017 /PRNewswire/ -- IsoRay Medical [ISR] Most American men will spend countless hours researching before making a major purchase whether it is a car, boat, motorcycle or a summer home. Yet, when it comes to their health, they merely accept the advice of their physician. 

The American Cancer Association published data shows nearly 200,000 cases of prostate cancer are diagnosed annually with one in seven men likely to be afflicted by the disease. Often, the options are either, invasive surgery, or extensive radiation treatment, both costly options. A treatment that has often been ignored is brachytherapy, which is not only more cost-effective but typically results in less treatment side-effects.

Around since the early 1900s, brachytherapy is a form of treatment that implants "seeds" directly into the tumorous tissue, these seeds deliver radiation doses to destroy cancer cells at the tumor site while limiting the damage to nearby healthy tissue. A recent study, Long-Term Quality of Life in Prostate Cancer Patients Treated with Cesium-131 by Glaser, et al., published in The International Journal of Radiation Oncology, Biology and Physics suggests that the newest brachytherapy isotope, Cesium-131, is changing the game.

"For far too long, patients have been treated for prostate cancer based on a medical professionals' familiarity or, in some cases, due to far greater financial benefits to the physician," said Dr. Brian Moran, medical director of the Chicago Prostate Cancer Center. "This study reinforces that a new, patient-friendly treatment exists. Brachytherapy with Cesium-131 leverages the isotope's short half-life to significantly reduce the duration of long-term symptoms and side effects."

Alternative brachytherapy isotopes deliver treatment over a lengthy time period, often with sustained side effects. Many physicians are starting to believe that Cesium-131, produced solely by Isoray Medical, is the ideal go-between – offering a highly targeted, fast-acting treatment with a shorter delivery time (30 days) than other isotopes used for brachytherapy, and, based on the recently published study, a quicker recovery period and ability for the patient to maintain his baseline quality of life over the long term.  

The fast-acting nature of the Cesium-131 seed treatment allows men to quickly recover from the short-term side-effects of radiation and return to normal urinary, bowel and sexual function faster than with other brachytherapy isotopes. Along with the recently published study, a growing body of literature supports faster recovery when Cesium-131 brachytherapy is utilized.

Since its inception, Isoray has leveraged the expertise in the Richland, Washington region to develop a proprietary process for manufacturing the new medical isotope, Cesium-131. With this advancement, Isoray has identified a more cost-effective cancer treatment solution for life beyond a patient's cancer.

About Isoray, Inc.
Isoray, Inc., through its subsidiary, Isoray Medical Inc., is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of Cesium-131 by visiting www.isoray.com. Join us on Facebook/Isoray. Follow us on Twitter @Isoray.

Safe Harbor Statement
Statements in this news release about IsoRay, Inc.'s future expectations, including: the advantages of our products and their delivery systems, whether the study will ultimately be completed, the cost effectiveness and side effect profiles, the other products' efficacy compared to our product, and the perception by the patient of quality of life outcomes or prove to be a safe approach compared to other treatment options, and all other statements in this release, other than historical facts, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). This statement is included for the express purpose of availing IsoRay, Inc. of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as physician acceptance, training and use of our products, our ability to successfully manufacture, market and sell our products, our ability to manufacture our products in sufficient quantities to meet demand within required delivery time periods while meeting our quality control standards, our ability to enforce our intellectual property rights, whether additional studies are released and support the conclusions of past studies, whether ongoing patient quality of life results with our products are favorable and in line with the conclusions of clinical studies and initial patient results, patient results achieved when our products are used for the treatment of cancers and malignant diseases in conjunction with other treatments, successful completion of future research and development activities, whether we, our distributors, and our customers will successfully obtain and maintain all required regulatory approvals and licenses to market, sell, and use our products in its various forms, continued compliance with ISO standards as audited by BSI, the success of our sales and marketing efforts, changes in reimbursement rates, changes in laws and regulations applicable to our products, and other risks detailed from time to time in IsoRay, Inc.'s reports filed with the SEC Securities and Exchange Commission. Unless required to do so by law, the Company IsoRay, Inc. undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

 

View original content with multimedia:http://www.prnewswire.com/news-releases/new-study-shows-brachytherapy-and-cesium-131-isotope-treatment-beneficial-for-prostate-cancer-patients-300497381.html

SOURCE IsoRay Medical

PR Newswire
www.prnewswire.com

Last updated on: 01/08/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.